Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma.
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Lenalidomide (Primary) ; Antithymocyte globulin; Ciclosporin; Fludarabine
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Therapeutic Use
- Acronyms LenaRIC
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 11 Jul 2017 Planned End Date changed from 30 Jun 2015 to 19 Dec 2017.
- 11 Jul 2017 Status changed from completed to active, no longer recruiting.